The CSE warmly welcomed Albert Labs International Corp. (CSE:ABRT) for a virtual Market Open on March 10, 2022.
Albert Labs is a research and drug development company addressing mental health care needs. Through a succinct clinical pathway, focusing on Real World Evidence (RWE), Albert Labs looks to commercialize its psychedelic-based treatments, and in doing so, deliver psychedelic-assisted psychotherapy to patients sooner.
CEO Dr. Michael Raymont and other members of the Albert Labs team kicked off the day’s trading at the virtual Market Open.
CSE CEO Richard Carleton noted, “Albert Labs represents another addition to the CSE’s growing stable of companies participating in the psychedelic market space. We look forward to working with the company as they pursue their research for psychedelic treatments that address critical mental health conditions.”
Dr. Raymont added, “We felt it was appropriate to get in front of the public to explain to investors and to the general public that this [work] is a real solution to an extremely serious problem. We really look forward to being a part of the CSE.”